LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	96M 187M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.03.2026 г., 19:32 ч. UTC

Придобивния, сливания и поглъщания

Diana Shipping Increases Offer to Acquire Genco -- Update

6.03.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6.03.2026 г., 22:26 ч. UTC

Значими събития в новините

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6.03.2026 г., 22:07 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.03.2026 г., 22:03 ч. UTC

Пазарно говорене

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

6.03.2026 г., 21:37 ч. UTC

Печалби

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6.03.2026 г., 21:25 ч. UTC

Значими събития в новините

How The Iran War Impacts Ukraine. -- Barrons.com

6.03.2026 г., 21:17 ч. UTC

Печалби

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6.03.2026 г., 20:50 ч. UTC

Печалби

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6.03.2026 г., 20:46 ч. UTC

Печалби

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6.03.2026 г., 20:31 ч. UTC

Значими събития в новините

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6.03.2026 г., 20:18 ч. UTC

Пазарно говорене

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6.03.2026 г., 20:12 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6.03.2026 г., 19:10 ч. UTC

Пазарно говорене

Значими събития в новините

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6.03.2026 г., 18:54 ч. UTC

Пазарно говорене

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6.03.2026 г., 18:44 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6.03.2026 г., 18:08 ч. UTC

Печалби

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6.03.2026 г., 18:04 ч. UTC

Печалби

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6.03.2026 г., 18:04 ч. UTC

Печалби

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6.03.2026 г., 17:49 ч. UTC

Пазарно говорене

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6.03.2026 г., 17:46 ч. UTC

Значими събития в новините

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6.03.2026 г., 17:40 ч. UTC

Пазарно говорене

Печалби

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6.03.2026 г., 17:40 ч. UTC

Печалби

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6.03.2026 г., 17:32 ч. UTC

Пазарно говорене

Значими събития в новините

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6.03.2026 г., 17:28 ч. UTC

Пазарно говорене

Значими събития в новините

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6.03.2026 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

6.03.2026 г., 17:20 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

6.03.2026 г., 17:20 ч. UTC

Придобивния, сливания и поглъщания

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.